No. patients | Age (yrs) | Female (%) | Patients with Cancer | Prevalence (%) | Expected prevalence (%) | Risk Ratio | |
---|---|---|---|---|---|---|---|
Minimal change | 428 | 43,3 ± 19 | 46 | 19 | 4,4 | 1.9 | 2.4 (1.4–3.7) c |
Endocapillary | 137 | 43,4 ± 18 | 53 | 7 | 5,1 | 1.7 | 3.0 (1.2–6.2) a |
Focal segmental glomerulosclerosis | 408 | 49,0 ± 17 | 34 | 27 | 6,6 | 2.7 | 2.4 (1.6–3.5) c |
Mesangioproliferative | 1185 | 42,2 ± 17 | 36 | 36 | 3,0 | 1.7 | 1,8 (1.2–2.5) b |
Membranous | 741 | 52,3 ± 17 | 41 | 37 | 5,0 | 3.2 | 1.5 (1.1–2.1) a |
Membranoproliferative | 298 | 49,2 ± 17 | 50 | 22 | 7,4 | 2.4 | 3.1 (1.9–4.7) c |
Proliferative | 113 | 43,4 ± 19 | 46 | 7 | 6,2 | 2.1 | 2.9 (1.2–6.0) a |
Focal segmental proliferative | 507 | 47,3 ± 19 | 36 | 15 | 3,0 | 2.3 | 1,3 (0.7–2.1) |
Focal | 146 | 56,1 ± 17 | 41 | 6 | 4,1 | 3.1 | 1.3 (0.5–1.8) |
Crescentic | 610 | 58,4 ± 16 | 39 | 27 | 4,4 | 3.9 | 1.1 (0.7–1.6) |
Unclassified | 552 | 55,4 ± 18 | 41 | 82 | 14,9 | 3.0 | 4.9 (3.9–6.1) c |
Anti-GBMGN | 92 | 55,5 ± 22 | 53 | 1 | 1,1 | 4.4 | 0.2 (0–1.4) |
ANCA associated vasculitis | 278 | 59,1 ± 16 | 38 | 21 | 7,6 | 4.2 | 1,8 (1.1–2.5) a |
Lupus nephritis unspecified | 99 | 38,1 ± 17 | 77 | 1 | 1,0 | 1.5 | 0,7 (0–3.8) |
Lupus nephritis all | 422 | 36.4 ± 15 | 77 | 7 | 1.7 | 0.7 | 1.2 (0.5–2.5) |
Any | 5594 | 49.4 ± 18 | 41 | 330 | 5.5 | 3.1 | 1,8 (1.4–2.1) c |